Maravai Lifesciences Holdings (MRVI) Income from Continuing Operations (2020 - 2026)
Maravai Lifesciences Holdings' (MRVI) quarterly Income from Continuing Operations came in at 6377000.0 in Q1 2026, up 87.93% year-on-year from 3393204.21 in Q1 2025, and up 89.88% quarter-over-quarter from 63015000.0 in Q4 2025.
Maravai Lifesciences Holdings (MRVI) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 6377000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 87.93% year-over-year to 6377000.0 in Q1 2026; TTM through Mar 2026 was 184286000.0, a 36.41% increase from a year earlier, with the FY2025 full-year figure at 230762000.0, up 11.12% from the prior year.
- Income from Continuing Operations grew to 6377000.0 in Q1 2026 per MRVI's latest filing, from 63015000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 156721000.0 in Q2 2022 and bottomed at 172455000.0 in Q3 2024.
- The 5-year median for Income from Continuing Operations is 18420000.0 (2024), against an average of 8498411.76.
- Across the five-year window, Income from Continuing Operations surged 94.61% in 2022 and slumped 1582.49% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 87429000.0 in 2022, then tumbled by 225.8% to 109982000.0 in 2023, then surged by 58.11% to 46067000.0 in 2024, then plunged by 36.79% to 63015000.0 in 2025, then surged by 89.88% to 6377000.0 in 2026.
- Per Business Quant, the three latest MRVI Income from Continuing Operations figures stand at 6377000.0 (Q1 2026), 63015000.0 (Q4 2025), and 45057000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Maravai Lifesciences Holdings | 1.03 Bn | 1.02 Bn | 33.70 Mn | -6.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.38 Mn |
| Dec 31, 2025 | -63.02 Mn |
| Sep 30, 2025 | -45.06 Mn |
| Jun 30, 2025 | -69.84 Mn |
| Mar 31, 2025 | -52.85 Mn |
| Dec 31, 2024 | -46.07 Mn |
| Sep 30, 2024 | -172.46 Mn |
| Jun 30, 2024 | -18.42 Mn |
| Mar 31, 2024 | -22.68 Mn |
| Dec 31, 2023 | -109.98 Mn |
| Sep 30, 2023 | -15.10 Mn |
| Jun 30, 2023 | -11.94 Mn |
| Mar 31, 2023 | -1.35 Mn |
| Dec 31, 2022 | 87.43 Mn |
| Sep 30, 2022 | 99.65 Mn |
| Jun 30, 2022 | 156.72 Mn |
| Mar 31, 2022 | 146.86 Mn |
| Dec 31, 2021 | 127.11 Mn |
| Sep 30, 2021 | 132.18 Mn |
| Jun 30, 2021 | 134.50 Mn |